Aditxt, Inc. Deferred Tax Assets, in Process Research and Development
Aditxt, Inc. (ADTX) had Deferred Tax Assets, in Process Research and Development of $3.23 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $3.23M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $4.16M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $3.23M 10-K · filed 2026-03-31 |
| 2024-12-31 | $4.16M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |